Search

Search Constraints

You searched for: Author/Creator Fox, Bernard

Search Results

41. New method for immunoprofiling of the tumor microenvironment of cancer patients by opal multiplex quantitative immunofluorescence (IF) assay. (4th November 2015)

42. New method for immunoprofiling of the tumor microenvironment of cancer patients by opal multiplex quantitative immunofluorescence (IF) assay. Issue 2 (December 2015)

43. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. Issue 1 (December 2016)

44. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015. Issue 1 (December 2016)

45. Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment. (4th November 2015)

46. Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment. Issue 2 (December 2015)

48. Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC. Issue 2 (December 2015)

49. Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC. (4th November 2015)

50. Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC. (6th November 2014)